Using Ga-68-CXCR4 PET/CT to improve detection of indolent B-cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of Ga-68-PentixaFor PET/CT imaging in detecting and monitoring indolent B-cell non-Hodgkin lymphoma. It aims to assess treatment responses and the potential for disease aggressiveness, addressing the limitations of the current FDG-PET imaging method, which is less accurate for low-grade lymphomas. Participants will undergo Ga-68-CXCR4 PET/CT scans as part of their clinical evaluation, particularly if they are scheduled for FDG PET scans within a specified timeframe.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL/SLL, mantle cell lymphoma.
* Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group.
* Able to lie flat for at least 30 minutes.
* Signing the subject consent form.
* ECOG grade 0-2.
* The timing of F-18-FDG usage in this trial follows the "Lymphoma Treatment Principles" of our institution.

Exclusion Criteria:

* Pregnant woman
* Severe renal impairment (eGRF\< 30ml/min)
* Known or suspected allergy to radiopharmaceuticals
* Concurrent or previous diagnosis of malignancies other than lymphoma
* Inability to undergo the necessary PET scan procedure
* Refusal or unwillingness to sign the informed consent form
* Severe medical conditions (severe disabilities, mental disorders)

Where it's running

• Koo Foundation Sun Yat-Sen Cancer Center
  Taipei, Beitou, Taiwan Recruiting

Study contacts

• Study coordinator: Yu Yi Huang, MD
• Email: yuyi@kfsyscc.org
• Phone: +886 28970011

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Reduced dose radiation therapy for indolent non-Hodgkin lymphoma

  This study is testing if a lower dose of radiation therapy can safely treat people with indolent non-Hodgkin lymphoma while causing fewer side effects.

  Recruiting at 6 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 6 other locations · NCT06386315

• Combination treatment for indolent B-cell non-Hodgkin lymphoma

  This study is testing a new combination of treatments for people with indolent B-cell non-Hodgkin lymphoma that hasn't responded to previous therapies to see if it can help them.

  Recruiting at 13 sites Phase 1/2 BioInvent International AB · Atlanta, Georgia and 26 other locations · NCT03571568

• Epcoritamab for B-cell lymphoma patients not fully responding to CAR-T therapy

  This study is testing if a new treatment called epcoritamab can help people with B-cell lymphoma who didn't fully respond to CAR-T therapy feel better and improve their chances of survival.

  Recruiting Phase 2 Academic and Community Cancer Research United · Rochester, Minnesota and 5 other locations · NCT06238648

• Combining three anti-cancer drugs for treating relapsed or refractory diffuse large B-cell lymphoma

  This study is testing a combination of three cancer drugs to see if they can help people with tough-to-treat diffuse large B-cell lymphoma feel better and respond to treatment.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 7 other locations · NCT06015880

• Tegavivint treatment for patients with relapsed or refractory large B-cell lymphoma

  This study is testing a new treatment called tegavivint to see if it can help people with relapsed or refractory large B-cell lymphoma feel better and how much of the drug is safe to use.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05755087

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.